NCT03000257 2022-04-14A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid TumorsAbbViePhase 1 Completed182 enrolled
NCT02709889 2020-10-19Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid TumorsAbbViePhase 1/2 Terminated200 enrolled 21 charts